|Biotech partner:||Epigenomics (Germany) Warnex Medical Laboratories (Canada)|
|Type of agreement:||* licensing
|Compound:||Septin9 biomarker for colorectal cancer blood test screening|
|Disease area:||colorectal cancer|
|Nature of the agreement:||Epigenomics and Warnex Medical Laboratories have signed a non-exclusive licensing agreement for Epigenomics'colorectal cancer biomarker Septin9. Under the terms of the agreement, Warnex has obtained the rights to establish a laboratory-developed test for Septin9 and offer colorectal cancer blood testing services in Canada.
Warnex plans to launch the testing service in the next few months. As the first laboratory to offer Septin9 testing in Canada, Warnex, subject to certain conditions, enjoys a time-limited head-start period of exclusivity for the Canadian market.
|Financial terms of the agreement:||Epigenomics will be entitled to certain royalty payments. Further contractual details were not disclosed.